NCT03606109View on ClinicalTrials.gov

Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

June 2, 2021

Study Completion Date

June 2, 2021

Conditions
Tibial Tubercle Osteotomy
Interventions
DRUG

Tranexamic Acid (TXA)

One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03606109 - Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid | Biotech Hunter | Biotech Hunter